Compare Charles Schwab Corporation Common Stock (SCHW) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Smith & Nephew plc — how do they compare? Charles Schwab Corporation Common Stock trades at $108.13 (market cap $186.25B), while Smith & Nephew plc trades at $29.63 (market cap $12.54B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 14.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| SCHW | SNN | |
|---|---|---|
Market Cap | $186.25B | $12.54B |
Sector | Financials | Health |
52-Week High | $108.02 | $38.70 |
52-Week Low | $85.35 | $28.73 |
Dividend Yield | 1.19% | 2.65% |
Enterprise Value | — | $15.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $107.99, up 0.36% today, near its all-time high. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels suggest overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.56 expected, and revenue growth accelerated to $23.92 billion in 2025. Analyst sentiment remains positive with a 56.87% buy rating and a $122.33 consensus price target, indicating potential upside.
The outlook for SCHW is favorable given robust earnings performance and upward revenue guidance, but risks include potential market volatility from economic data and ongoing litigation. Institutional buying and a high ROE of 22.45% support the bullish case, though investors should monitor inflation reports and insider selling activity for near-term cues.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
